Royal DSM N.V. has repurchased 298,333 of its own shares in the period from 5 May 2008 up to and including 7 May 2008 at an average price of EUR 35.46. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces that the company will today, 5 May 2008, start the second phase of the share buy-back program of EUR 750 million announced on 27 September 2007.

Organic sales growth 14% due to strong business positions and favorable market conditions. EBIT from continuing operations up 22% despite lower US dollar and higher feedstock prices. Earnings per share up 42%. Execution of Vision 2010 strategy fully on track. Resumption of share buy-back program for next EUR 250 million as of 5 May. Outlook: 2008 EBIT expected to be EUR 870 million +/- 5%.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces an agreement to acquire The Polymer Technology Group, Inc. (PTG) of Berkeley (California, United States).

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announced the opening of the market development plant for PA4T, the new polymer for use in electronics and other applications. The plant is operational as of today.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces plans for a substantial capital expenditure program, expected to involve up to USD 450 million.

Royal DSM N.V. announces the following management appointments: Jos Goessens (1951), at present Business Group Director DSM Engineering Plastics, has been appointed Director Strategic Projects, reporting to the Managing Board. Roelof Westerbeek (1963) has been appointed Business Group Director DSM Engineering Plastics with effect from 1 October 2008.

Royal DSM N.V. today provides the investment community with comparative figures for 2007 that reflect the company’s new cluster structure as of 1 January 2008. The new structure was announced in September 2007 and is a result of the acceleration of DSM’s strategy Vision 2010 – Building on Strengths.

The DSM Annual General Meeting of Shareholders on 26 March 2008 passed a resolution to declare a dividend for 2007 of EUR 1.20 per ordinary share of EUR 1.50 par value. An interim dividend of EUR 0.33 per ordinary share having been paid on 22 August 2007, the final dividend for 2007 will amount to EUR 0.87 per ordinary share.

Royal DSM N.V. today held its Annual General Meeting of Shareholders.

At the Annual General Meeting being held later today, DSM will provide a trading update for 2008.

Royal DSM N.V. is today presenting its fifth annual sustainability report: the Triple P (People, Planet, Profit) Report 2007 entitled Embracing the Future.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has made an equity investment in the Dutch company IQ Therapeutics B.V.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a USD 20 million financing round in Tianjin Green Bio-Science Co., Ltd (China).

DSM, the innovative partner in sports of the Dutch Olympic Committee (NOC*NSF), is presenting a number of major innovations for the sport of sailing

The Dutch Ministers Cramer (Housing, Spatial Planning and the Environment) and Eurlings (Transport, Public Works and Water Management) and DSM today announce that they have reached an agreement in principle on the termination of ammonia transport by rail between Geleen and IJmuiden.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, has reached an agreement in principle with Arsenal Capital Partners (United States) on the sale of DSM Special Products BV.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, has received a grant from the US Department of Energy for a technical consortium on an innovative biotechnological approach of bioproducts and biofuels.

DSM proposes appointing Mrs Louise Gunning-Schepers as a member of its Supervisory Board.

Strong Q4 results based on 10% organic sales growth. Operating profit for 2007 of EUR 823 million in line with expectations. Net profit before exceptional items at EUR 558 million, better than last year; EPS 8% higher. Proposed dividend EUR 1.20 per ordinary share (+20%). Outlook: Operating profit before exceptional items in 2008 expected to approach level achieved in 2007.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and the French starch and starch-derivatives company ROQUETTE have joined forces to implement and commercialize the fermentative production of biorenewable succinic acid, which – amongst other applications - opens the possibility to produce bio-based performance materials.

Royal DSM N.V., the leading Life Sciences and Materials Sciences company from the Netherlands, today announces the acquisition of the US-based company Soluol, a developer, producer and marketer of high performance urethane resins which are used in a wide range of applications, with annual sales of USD 20 million.

Royal DSM N.V., the leading Life Sciences and Materials Sciences company from the Netherlands, today announces that it will invest nearly EUR 15 million in the construction of a new plant for the production of wet polyesters and other specialty resins in Meppen, Germany.